Recent News Of Invokana Lawsuit Calls Focus To Potential Heart Attack Side Effects Noted During Clinical Trials

March 31, 2016 – – TheProductLawyers.com discusses reported clinical trial indications of increased heart attack risks within the initial 30 days of treatment among patients using Invokana. Invokana is a new-generation, type-2 diabetes drug manufactured by Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation). The noted risks were highlighted during the drug’s clinical trials, apparently connecting the use of the drug to possible heart issues.

In March of 2013, Invokana was the first of a group of similar SGLT2 class inhibitor drugs to be approved by the U.S. Food and Drug Administration (FDA) and released to market for public use. It was reported, however, that during clinical trials conducted on the drug, 13 patients using it suffered from major cardiovascular events (such as heart attacks or strokes) within their initial 30 days of treatment. Results also showed that after this 30-day time period, the risk for these events to occur suddenly equalized.

The New York Times addressed these findings and the apparent lack of a warning that they may occur on the drug’s label, noting, “The label of the drug includes no warnings about heart attacks or strokes. …The FDA is requiring Johnson & Johnson to conduct five post-marketing studies, including a clinical trial to determine more definitively if the drug increases those risks.”

Heart attacks are caused when something inside a patient’s body stops blood flow to their heart. This blockage is typically caused by blood clots. Because it stops the heart from obtaining enough oxygen, the muscle of the heart starts to die. If severe tissue damage is sustained during this time, the heart will be unable to pump blood through the body, and the heart attack could become fatal.

The attorneys of Banville Law understand how concerning this potential side effect link is for patients currently using Invokana, especially those within their first 30 days on the medication. They are dedicated to keeping the public informed regarding Invokana information or important information on other drugs. To accomplish this, they sponsor the website TheProductLawyers.com. At this time, the attorneys of Banville Law are also working to help those who have taken Invokana or similar SGLT2 class inhibitor drugs and who have experienced health problems that they believe were caused by the drugs. They hope to help ensure that affected individuals are given the opportunity to investigate their legal rights in the matter. These individuals may be entitled to significant compensation through legal action. To help those wishing to discuss this possibility, the attorneys of Banville Law are offering complimentary Invokana consultations at this time.

To ask questions or request additional information on Invokana lawsuits, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009004